Poterepatide (HDM1005)_Dosage, benefits & legal status
Also known as HDM1005, HDM-1005
A dual agonist that stopped gaining above 2 mg.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Poterepatide (HDM1005)?
Plain language first. The technical label stays, but it never stands alone.Overview
This is a once-weekly Chinese weight-loss injection hitting the same two receptors as tirzepatide, and unlike most of its Chinese rivals its chemical identity is properly published in a peer-reviewed journal. The interesting thing in its data is where the curve stops. Across four doses the weight loss climbed from about 7% to about 13%, then stopped: the 2 mg and 4 mg groups came out the same, and the proportion of people losing at least a tenth of their body weight was actually lower on the higher dose. Doubling the dose bought nothing. There is also a late-stage trial the company says succeeded, announced without a single number, and a separate Huadong drug with an almost identical code that is routinely mixed up with this one.
Poterepatide, development code HDM1005, is a synthetic GLP-1 and GIP dual receptor agonist from Huadong Medicine, dosed subcutaneously once weekly. A peer-reviewed paper from the company's own research center establishes its identity: it is a synthetic peptide acylated at lysine 24, not a fusion protein, discovered through a molecular dynamics approach and characterized there as a balanced dual agonist. That paper reports a mouse half-life of roughly 20 to 23 hours against about 9 hours for tirzepatide, though all of its figures are preclinical and murine. Despite wide use of the name, poterepatide appears on no WHO International Nonproprietary Name list, proposed or recommended, so it is a development name rather than an established INN.
What it's used for
Investigational for obesity and for type 2 diabetes. Not approved anywhere and not sold.
How does Poterepatide (HDM1005) work?
What it does in the body, and where.The receptor targets are the familiar pair. What this compound offers that most of its Chinese rivals do not is a published account of its own chemistry, and a dose-response curve honest enough to show where it stops.
- 01A fatty acid on lysine 24This is a synthetic peptide carrying an acyl chain at lysine 24, the same half-life strategy semaglutide uses. The attached fatty acid binds albumin in the bloodstream, so the molecule travels bound to a large carrier protein and escapes kidney filtration and enzymatic attack. That is a different approach from fusing the peptide to an antibody fragment, and it keeps the molecule small enough to be made by chemical synthesis.
- 02Balanced rather than biasedThe company's own paper in a peer-reviewed chemistry journal describes the molecule as a high-potency balanced GLP-1 and GIP dual agonist, found through a molecular dynamics approach. Balanced means comparable activity at both receptors. It is worth noting the contrast with its closest Chinese rival, whose conference abstract describes that molecule as biased instead. Neither characterization is backed by receptor signaling data a reader can check, so both are best treated as the developers' descriptions.
- 03The curve flattens at 2 mgIn 243 people over 22 weeks the weight loss ran 7.38% at 0.5 mg, 9.61% at 1 mg, 13.21% at 2 mg and 13.32% at 4 mg, against 2.45% on placebo. The last step is the interesting one: doubling from 2 to 4 mg added about one tenth of a percentage point. The proportion of people losing at least 10% of their weight tells the same story more sharply, rising 24.0%, 52.1%, 75.0% and then falling to 70.8%. A flattening curve is useful information, because it suggests the useful dose ceiling has been found rather than that more would be better.
- 04What the mouse data can and cannot tell youThe published paper reports a half-life of roughly 20 to 23 hours in mice against about 9 hours for tirzepatide in the same experiments. That is a real comparison and a reasonable basis for weekly dosing in people, since small animals clear peptides far faster than humans do. It is not a human pharmacokinetic result, and no human half-life for this compound has been published.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
The dose-response stops at 2 mg
peer-reviewed-human- Human trial243 participants, 22 weeks: weight loss 7.38%, 9.61%, 13.21% and 13.32% at 0.5, 1, 2 and 4 mg against 2.45% on placebo.
- Human trialShare losing at least 10% of body weight: 24.0%, 52.1%, 75.0% then 70.8%, so the top dose performed worse on this measure than 2 mg.
- Human trialNausea 2.1% to 18.8% against 2.0% on placebo, with no permanent discontinuations attributed to adverse events.
Identity is published, unusually for this group
peer-reviewed-human- lab-analysisA peer-reviewed paper from the company's own research center names HDM1005 as poterepatide and establishes it as a synthetic peptide acylated at lysine 24, not a fusion protein.
- Animal studyThe same paper reports a mouse half-life of roughly 20 to 23 hours against about 9 hours for tirzepatide. Preclinical and murine, not human.
- No dataPoterepatide appears on no WHO International Nonproprietary Name list, so calling it the compound's INN overstates its status.
The phase 3 claim cannot be checked
Investigational- No dataA 40-week phase 3 interim was announced as having met its primary endpoint with zero figures disclosed.
- No dataThe registry record for that trial describes no interim analysis and states the trial has no data monitoring committee.
- RegulatoryThe furthest regulatory step is a pre-new-drug-application communication request planned for the fourth quarter of 2026 and not yet submitted.
The look-alike code
none- No dataHDM1002 is a separate Huadong compound: taken by mouth and not a peptide, with its own results and its own filing timeline.
- No dataA September 2026 company report presents this compound's figure-free interim immediately followed by HDM1002's week 52 results of 10.7% and 12.2% against 1.2% placebo. Those numbers belong to the oral drug.
- No dataA March 10, 2026 date circulates for the phase 2 announcement and could not be verified. The documented dates are December 15, 2025 for the topline and June 5, 2026 for the obesity presentation.
The most useful correction is about dose. The weight-loss figure usually quoted for this compound is around 13%, and that is right, but it is reached at 2 mg and does not improve at 4 mg: the two doses produced 13.21% and 13.32%, and the proportion of people losing at least a tenth of their body weight was actually lower at the top dose. The second is the phase 3 claim. An interim analysis at 40 weeks was announced as successful with no figures at all, and the registry record for that trial describes no interim analysis and states it has no data monitoring committee, so nothing about that announcement can be checked. The third is the name: poterepatide appears on no WHO International Nonproprietary Name list, proposed or recommended, so it is a development name rather than an established INN, the opposite of its closest rival RAY1225, whose name bilpatide was formally proposed in July 2026. The fourth is the half-life, taken from mice with no published human counterpart. The fifth, and the easiest to fall into, is mixing it up with HDM1002: a separate Huadong drug taken by mouth and not a peptide, whose week 52 figures of 10.7% and 12.2% get attached to this compound because a company report presents them a few lines apart. A March 10, 2026 announcement date also circulates and could not be verified anywhere.
The published record
Papers about Poterepatide (HDM1005)
Searched: poterepatide, HDM1005.
Left out: HDM1002 (observed conflation and the single most important rejection here. A DIFFERENT Huadong compound, taken by mouth and not a peptide. A September 2026 company report prints HDM1005's figure-free phase 3 interim and then HDM1002's week 52 results of 10.7%/12.2% against 1.2% placebo a few lines apart, so those numbers get attached to the wrong drug); HDM (the bare company code stem, matching at least two unrelated programs); tirzepatide (the class benchmark and the comparator in the preclinical paper, with an enormous literature of its own); GIP (the receptor class term shared across the dual agonist class); GLP-1 (the receptor class term, tens of thousands of records); Huadong (the parent company, whose metabolic portfolio includes HDM1002 and, through a separate subsidiary, DR10624).
14 papers tagged human · 1 not reviews or lab · 0 clinical trial publications
13 registered trials · none with posted results
Furthest stage reached: Phase 3, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.
At a glance
Four things to know about Poterepatide (HDM1005)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 20 to 23 hours in mice; no human figure published
How much, and do you cycle it?
The range, and whether you take breaks.0.5 to 4 mg weekly across the phase 2 dose range, once weekly. Continuous weekly dosing in trials Trial dose
Trialed as a chronic weekly treatment, titrated upward rather than cycled.
How long does it stay in the body?
The half-life, and where the figure comes from.About 20 to 23 hours in mice; no human figure publishedAnimal study
These numbers are from mice, measured alongside tirzepatide at about 9 hours in the same experiments, so the comparison is internally consistent but the species is not human. Small animals clear peptides much faster than people do, so a 20 to 23 hour mouse half-life is compatible with weekly dosing in humans without implying anything numerical about the human value. No human half-life for this compound has been published.
Source: Journal of Medicinal Chemistry 2026, volume 69, pages 11672 to 11686, DOI 10.1021/acs.jmedchem.6c00466
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Investigational and not sold, so no vial draw can be shown and the calculator does not apply. The published phase 2 tested 0.5, 1, 2 and 4 mg once weekly over 22 weeks. No dose amounts appear in any registry record for this compound.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
Poterepatide (HDM1005) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Reading the phase 3 interim announcement as a result, since it disclosed no figures and the registry record for that trial describes no interim analysis and states it has no data monitoring committee
- Assuming more dose means more weight loss, since 4 mg matched 2 mg and had a lower proportion of people reaching 10% loss
- Confusing it with HDM1002, a separate Huadong compound that is an oral non-peptide drug with its own results and its own filing
Stop and get help
- Severe or persistent abdominal pain, a possible sign of pancreatitis in this drug class
- Persistent vomiting with an inability to keep fluids down
- Signs of an allergic reaction, including rash, swelling or difficulty breathing
Common effects
- Nausea, reported at 2.1% to 18.8% across doses against 2.0% on placebo.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Poterepatide (HDM1005) approved?
And where the numbers on this page come from.No. Poterepatide (HDM1005) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous injection, once weekly)
- Checked2 November 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Nothing is approved. The compound holds four US investigational new drug applications and four Chinese ones, and as of the company's late September 2026 report the furthest regulatory step was a pre-new-drug-application communication request planned for the fourth quarter of 2026 and not yet submitted. A 40-week phase 3 obesity interim analysis was reported as having met its primary endpoint with no figures disclosed, and the corresponding registry record describes no interim analysis and states that the trial has no data monitoring committee, so that announcement cannot be checked against the registered design. Two naming points matter. Poterepatide appears on no WHO International Nonproprietary Name list, so describing it as this compound's INN overstates its status; the name's substantive anchor is the company's own journal paper. Separately, a date in circulation placing the phase 2 announcement on March 10, 2026 could not be verified in Chinese or English sources. The documented dates are phase 1 results at a June 2025 conference, a phase 2 weight-management topline on December 15, 2025, and the phase 2 obesity presentation on June 5, 2026. Finally, the compound must not be confused with HDM1002, a separate Huadong drug taken by mouth and not a peptide. The confusion risk is concrete: a September 2026 company report presents this compound's figure-free phase 3 interim immediately followed by HDM1002's week 52 results of 10.7% and 12.2% against 1.2% on placebo and its imminent new drug application. Those numbers belong to the oral drug.
You can compare this against the whole library, or read how to check a seller.
What else is like Poterepatide (HDM1005)?
Others in GLP-1 agonists, side by side.If you're weighing Poterepatide (HDM1005), it's worth reading RAY1225 (Bilpatide), Ribupatide, and VK2735 in the same class.
A dual agonist that stopped gaining above 2 mg.
- Dose
- 0.5 to 4 mg weekly across the phase 2 dose range
- How often
- Once weekly
A fortnightly dual agonist with a topline nobody can place in time.
- Dose
- 3 to 18 mg every 2 weeks across the phase 2 dose range
- How often
- Every 2 weeks
An experimental weekly GLP-1/GIP shot from China, now in a 4,900-person phase 3 program.
- Dose
- 2 up to 10 mg per week (trial doses)
- How often
- Weekly
An experimental weight-loss compound in the tirzepatide family, as a shot or pill.
- Dose
- 2.5 up to 15 mg per week (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Journal of Medicinal Chemistry, discovery of a high-potency balanced GLP-1 / GIP dual agonist(2026)Volume 69, pages 11672 to 11686, PMID 42125916, all authors from Huadong's global research center. The paper that establishes this compound's identity: it names HDM1005 as poterepatide and describes a synthetic peptide acylated at lysine 24, discovered through a molecular dynamics approach, characterized as a balanced dual agonist. It reports a mouse half-life of roughly 20 to 23 hours against about 9 hours for tirzepatide. All figures in it are preclinical and murine. Having a published chemical identity puts this compound ahead of most of its Chinese rivals on verifiability.
- Diabetes, abstract 1034-OR, HDM1005 phase 2 in obesity(2026)Volume 75, issued June 5, 2026. The phase 2 in 243 participants at 0.5, 1, 2 and 4 mg once weekly over 22 weeks: weight loss 7.38%, 9.61%, 13.21% and 13.32% against 2.45% on placebo. The proportion losing at least 10% ran 24.0%, 52.1%, 75.0% and 70.8% against 6.1%. Nausea 2.1% to 18.8% against 2.0%, with no permanent discontinuations attributable to adverse events. Note the plateau between 2 and 4 mg and the lower responder rate at the top dose. This issue date also matters because it contradicts a March 2026 announcement date that circulates for these results.
- ClinicalTrials.gov record NCT07279194, the phase 3 obesity trial(2026)The registry record for the phase 3 whose 40-week interim analysis was announced as having met its primary endpoint. The record describes no interim analysis and states that the trial has no data monitoring committee, so the announcement cannot be reconciled with the registered design. No figures were disclosed with that announcement, and no results are posted.
Beyond these, 14 records are indexed. Browse the records